Current Affairs - International - Discussion

The approval of mitapivat as the first oral treatment for anaemia in adults with alpha- and beta-thalassemia marks a significant advancement in patient care. The decision was taken by the drug regulatory authority of the United States, reflecting its role in evaluating and approving innovative medical therapies. The oral pill benefits both transfusion-dependent and non-transfusion-dependent patients by improving haemoglobin levels and reducing fatigue. This development is expected to decrease dependence on regular blood transfusions and promote more patient-centric, convenient management of thalassemia.